+34 963 586 020
  • English
    • English
    • Español
    • عربي

We advise all cancer patients to read this IMPORTANT book about the reality of cancer. CANCER: THE SURPRISING TRUTH. Its author is the prestigious molecular biologist Travis Christofferson. We recommend it for all cancer patients and of course for all physicians and oncologists.

Many of these treatments will require authorization from the Ministry of Health (Spanish Agency for Medicines and Health Products) in order to be administered under the legal figure of ‘COMPASSIONATE USE’.
For this purpose, a dossier will be sent with all the necessary information about the patient, their pathology and the drug to be used, while awaiting authorization for its use.

CANCER: THE SURPRISING TRUTH

Metronomic chemotherapy

Metronomic chemotherapy is the term used when the different chemotherapy drugs are administered in small doses of low intensity, so that the side effects are very slight or almost non-existent and, therefore, this treatment can be considered for longer periods of time, and toxicity is minimal.

As this method is applied in low doses, there is less risk of adverse reactions, which allows us to administer a treatment in a more continuous manner being equally effective and with less toxicity.

This type of chemotherapy has been demonstrated to have an immunostimulatory effect on the patient, which is not incompatible with intratumoral treatment with immunotherapeutics.

Metronomic chemotherapy improves the patient's quality of life by using substances that are available as generics, so the cost of treatment is significantly lower.

The aim of this chemotherapy is to prevent the reproduction of cancerous cells. Nowadays, metronomic chemotherapy is used as the last therapeutic method when other treatment options have been exhausted, but researchers consider that it could be applied in earlier stages.

This regimen is already practiced by many oncologists around the world and has also been used in many public hospitals in Spain since 2021.

  • Researchers from the Spanish Lung Cancer Group (GECP) publish in the journal Lung Cancer the results of the NORA study, the first worldwide to confirm the benefits of so-called ‘metronomic chemotherapy’ for patients with locally advanced inoperable lung cancer.
  • This type of chemotherapy allows low doses of several drugs to be combined in uninterrupted sessions, reducing the risk of adverse reactions and being potentially effective.
  • The GECP researchers treated a total of 65 patients with two different drugs along with low-dose radiotherapy sessions, achieving survival and disease progression results similar to standard treatment, but reducing toxicity by 80%.
  • The NORA study by the GECP also evaluated the correlation between circulating tumor DNA (ctDNA) levels and survival, paving the way for the standardization of liquid biopsy use as a tool to monitor treatment response.
quimio-metronomica

BIBLIOGRAPHY

Request information without obligation

Request information without obligation, we will study your case with our medical team to give you an answer as soon as possible.

250
I accept the terms of use and privacy policy
mmoncoproject.com
Calendly